nach oben

Erschienen in:

01.06.2011 | Original Article

Prognostic Value of Primary Tumor Uptake on F-18 FDG PET/CT in Patients with Invasive Ductal Breast Cancer

verfasst von: Bong-Il Song, Chae Moon Hong, Hong Je Lee, Sungmin Kang, Shin Young Jeong, Hae Won Kim, Yee Soo Chae, Ji Young Park, Sang-Woo Lee, Byeong-Cheol Ahn, Jaetae Lee

Erschienen in: Nuclear Medicine and Molecular Imaging | Ausgabe 2/2011

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To determine the prognostic implications of pretreatment F-18 FDG PET/CT in patients with invasive ductal breast cancer (IDC), we evaluated the relationship between FDG uptake of the primary tumor and known prognostic parameters of breast cancer. Prognostic significance of tumoral FDG uptake for the prediction of progression-free survival (PFS) was also assessed.

Materials and Methods

Fifty-five female patients with IDC who underwent pretreatment F-18 FDG PET/CT were enrolled. The maximum standardized uptake value of the primary tumor (pSUVmax) was compared with clinicopathological parameters including tumor size, grade, estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor2 (HER2), axillary lymph node (LN) metastasis, and stage. The prognostic value of pSUVmax for PFS was assessed using the Kaplan-Meier method.

Results

A high pSUVmax was significantly related to a higher stage of tumor size (P < 0.05), grade (P < 0.001), and stage (P < 0.001). pSUVmax was significantly higher in ER-negative tumors (P < 0.001), PR-negative tumors (P < 0.001), and positive LN metastasis (P < 0.01), but not different according to HER2 status. pSUVmax was significantly higher in patients with progression compared to patients who were disease-free (10.6 ± 5.1 vs. 4.7 ± 3.5, P < 0.001). A receiver-operating characteristic curve demonstrated a pSUVmax of 6.6 to be the optimal cutoff for predicting PFS (sensitivity; 86.7%, specificity; 82.5%). The patients with a high pSUVmax (more than 6.6) had significantly shorter PFS compared to patients with a low pSUVmax (P < 0.0001).

Conclusions

pSUVmax on pretreatment F-18 FDG PET/CT could be used as a good surrogate marker for the prediction of progression in patients with IDC.

Desantis C, Center MM, Siegel R, Jemal A. American Cancer Society. Breast Cancer Facts & Figures 2009–2010 Atlanta: American Cancer Society, Inc. http://www.cancer.org/acs/groups/content/@nho/documents/document/f861009final90809pdf.pdf

Lavayssière R, Cabée AE, Filmont JE. Positron emission tomography (PET) and breast cancer in clinical practice. Eur J Radiol. 2009;69:50–8.PubMedCrossRef

Geus-Oei LF, Oyen WJ. Predictive and prognostic value of FDG-PET. Cancer Imaging. 2008;8:70–80.PubMedCrossRef

Allal AS, Slosman DO, Kebdani T, Allaoua M, LehmannW DP. Prediction of outcome in head-and-neck cancer patients using the standardized uptake value of 2-[¹⁸F]fluoro-2-deoxy-D-glucose. Int J Radiat Oncol Biol Phys. 2004;59:1295–300.PubMedCrossRef

Downey RJ, Akhurst T, Gonen M, Vincent A, Bains MS, Larson S, et al. Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J Clin Oncol. 2004;22:3255–60.PubMedCrossRef

Sasaki R, Komaki R, Macapinlac H, Erasmus J, Allen P, Forster K, et al. [¹⁸F] fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol. 2005;23:1136–43.PubMedCrossRef

Vansteenkiste JF, Stroobants SG, Dupont PJ, De Leyn PR, Verbeken EK, Deneffe GJ, et al. Prognostic importance of the standardized uptake value on F-18 fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: an analysis of 125 cases. Leuven lung cancer group. J Clin Oncol. 1999;10:3201–6.

Nguyen XC, Lee WW, Amin AM, Eo JS, Bang SM, Lee JS, et al. Tumor burden assessed by the maximum standardized uptake value and greatest diameter on FDG-PET predicts prognosis in untreated diffuse large B-cell lymphoma. Nucl Med Mol Imaging. 2010;44:39–44.CrossRef

Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2007;131:18–43.PubMed

10.

Minn H, Zasadny KR, Quint LE, Wahl RL. Lung cancer: reproducibility of quantitative measurements for evaluating 2-[F-18]-fluoro-2-deoxy-D-glucose uptake at PET. Radiology. 1995;196:167–73.PubMed

11.

Ikenaga N, Otomo N, Toyofuku A, Ueda Y, Toyoda K, Hayashi T, et al. Standardized uptake values for breast carcinomas assessed by fluorodeoxyglucose-positron emission tomography correlate with prognostic factors. Am Surg. 2007;73:1151–7.PubMed

12.

Mavi A, Cermik TF, Urhan M, Puskulcu H, Basu S, Yu JQ, et al. The effects of estrogen, progesterone, and C-erbB-2 receptor states on ¹⁸F-FDG uptake of primary breast cancer lesions. J Nucl Med. 2007;48:1266–72.PubMedCrossRef

13.

Gil-Rendo A, Martínez-Regueira F, Zornoza G, García-Velloso MJ, Beorlegui C, Rodriguez-Spiteri N. Association between [¹⁸F]fluorodeoxyglucose uptake and prognostic parameters in breast cancer. Br J Surg. 2009;96:166–70.PubMedCrossRef

14.

Oshida M, Uno K, Suzuki M, Nagashima T, Hashimoto H, Yagata H, et al. Predicting the prognoses of breast carcinoma patients with positron emission tomography using 2-deoxy-2-fluoro[18 F]-D-glucose. Cancer. 1998;82:2227–34.PubMedCrossRef

15.

Ueda S, Tsuda H, Asakawa H, Shigekawa T, Fukatsu K, Kondo N, et al. Clinicopathological and prognostic relevance of uptake level using ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18 F-FDG PET/CT) in primary breast cancer. Jpn J Clin Oncol. 2008;38:250–8.PubMedCrossRef

16.

Inoue T, Yutani K, Taguchi T, Tamaki Y, Shiba E, Noguchi S. Preoperative evaluation of prognosis in breast cancer patients by [¹⁸F]2-Deoxy-2-fluoro-D-glucose-positron emission tomography. J Cancer Res Clin Oncol. 2004;130:273–8.PubMedCrossRef

17.

Kawamura T, Kusakabe T, Sugino T, Watanabe K, Fukuda T, Nashimoto A, et al. Expression of glucose transporter-1 in human gastric carcinoma: association with tumor aggressiveness, metastasis, and patient survival. Cancer. 2001;92:634–41.PubMedCrossRef

18.

Cerfolio RJ, Bryant AS. Maximum standardized uptake values on positron emission tomography of esophageal cancer predicts stage, tumor biology, and survival. Ann Thorac Surg. 2006;82:391–5.PubMedCrossRef

19.

Minn H, Lapela M, Klemi PJ, Grénman R, Leskinen S, Lindholm P, et al. Prediction of survival with fluorine-18-fluoro-deoxyglucose and PET in head and neck cancer. J Nucl Med. 1997;38:1907–11.PubMed

20.

Cerfolio RJ, Bryant AS, Ohja B, Bartolucci AA. The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival. J Thorac Cardiovasc Surg. 2005;130:151–9.PubMedCrossRef

21.

Basu S, Chen W, Tchou J, Mavi A, Cermik T, Czerniecki B, et al. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization. Cancer. 2008;112:995–1000.PubMedCrossRef

22.

Toikkanen S, Pylkkanen L, Joensuu L. Invasive lobular carcinoma of the breast has better short- and long-term survival than invasive ductal carcinoma. Br J Cancer. 1997;76:1234–40.PubMedCrossRef

Titel: Prognostic Value of Primary Tumor Uptake on F-18 FDG PET/CT in Patients with Invasive Ductal Breast Cancer
verfasst von: Bong-Il Song
Chae Moon Hong
Hong Je Lee
Sungmin Kang
Shin Young Jeong
Hae Won Kim
Yee Soo Chae
Ji Young Park
Sang-Woo Lee
Byeong-Cheol Ahn
Jaetae Lee
Publikationsdatum: 01.06.2011
Verlag: Springer-Verlag
Erschienen in: Nuclear Medicine and Molecular Imaging / Ausgabe 2/2011
Print ISSN: 1869-3474
Elektronische ISSN: 1869-3482
DOI: https://doi.org/10.1007/s13139-011-0081-0

Springer Medizin

Abstract

Purpose

Materials and Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2011

18F-FDG PET/CT Findings in a Breast Cancer Patient with Concomitant Tuberculous Axillary Lymphadenitis

Total Thyroidectomy in the Mouse: the Feasibility Study in the Non-thyroidal Tumor Model Expressing Human Sodium/Iodide Symporter Gene

Potential Biomarker of L-type Amino Acid Transporter 1 in Breast Cancer Progression

Development of 166Ho-phytate Complex for Radiosynovectomy

Intratumoral Heterogeneous F-18 Fluorodeoxyglucose Uptake Corresponds with Glucose Transporter-1 and Ki-67 Expression in a Case of Krukenberg Tumor: Localization of Intratumoral Hypermetabolic Focus by Fused PET/MR Image

Detection of Thyroid Metastasis of Renal Transitional Cell Carcinoma Using FDG PET/CT